Global Head and Neck Cancer Therapeutics Market Report 2022: Advances in Biochemistry and Genomics Fuels Sector
16 sept. 2022 08h23 HE | Research and Markets
Dublin, Sept. 16, 2022 (GLOBE NEWSWIRE) -- The "Head and Neck Cancer Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report aims to provide a...
Nouveau Logo communiqué de presse.JPG
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
12 sept. 2022 07h30 HE | Theratechnologies
Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...
Nouveau Logo communiqué de presse.JPG
L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale
12 sept. 2022 07h30 HE | Theratechnologies
Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...
Global Head & Neck Cancer Drugs Market (2022 to 2027) - Featuring AbbVie, Amgen and Gilead Sciences Among Others
24 août 2022 05h08 HE | Research and Markets
Dublin, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The "Global Head & Neck Cancer Drugs Market (2022-2027) by Drug Class, Product, End User, Geography, Competitive Analysis and the Impact of Covid-19...
Spexis logo.png
Spexis' CXCR4 inhibitor balixafortide demonstrates synergistic efficacy in combination with docetaxel in a metastatic prostate cancer preclinical model
07 juil. 2022 01h30 HE | Spexis AG
ALLSCHWIL, Switzerland, July 07, 2022 (GLOBE NEWSWIRE) -- SPEXIS AG (SIX: SPEX), a clinical-stage biopharmaceutical company, today announced that its CXCR4 inhibitor balixafortide demonstrated...
22157.jpg
Global Head & Neck Cancer Drugs Market Research Report (2021 to 2026) - by Drug Class, Product, End-user and Region
05 janv. 2022 06h33 HE | Research and Markets
Dublin, Jan. 05, 2022 (GLOBE NEWSWIRE) -- The "Head & Neck Cancer Drugs Market Research Report by Drug Class, Product, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of...
22157.jpg
Investigation Report on China's CNY1.112 Billion Docetaxel Market 2021-2025
31 déc. 2021 05h43 HE | Research and Markets
Dublin, Dec. 31, 2021 (GLOBE NEWSWIRE) -- The "Investigation Report on China's Docetaxel Market 2021-2025" report has been added to ResearchAndMarkets.com's offering. According to the market...
LIDDS announces positive topline results from the phase I dose-escalating study of NanoZolid®-formulated docetaxel
29 déc. 2021 04h00 HE | LIDDS AB
UPPSALA, SWEDEN – LIDDS AB (publ) announced today that the systemic exposure of docetaxel after treating solid tumors with NanoZolid®-docetaxel is low and that the study demonstrated activity in both...
LIDDS tillkännager positiva topline resultat från den dos-eskalerande fas I studien av NanoZolid®-formulerad docetaxel
29 déc. 2021 04h00 HE | LIDDS AB
UPPSALA, SVERIGE – LIDDS AB (publ) tillkännagav i dag att den systemiska exponeringen av docetaxel efter behandling av solida tumörer med NanoZolid®-formulerad docetaxel är låg och att studien visar...
22157.jpg
Global Prostate Cancer Clinical Landscape Market Report 2021: Treatments, Epidemiology, Marketed Drugs, Pipeline Drugs, Regulatory Events, Clinical Trials, Drug Assessment, Future Trends
14 juil. 2021 05h03 HE | Research and Markets
Dublin, July 14, 2021 (GLOBE NEWSWIRE) -- The "Disease Analysis: Prostate Cancer" report has been added to ResearchAndMarkets.com's offering. The publisher estimates that in 2018, there were 1.3...